Role of preoperative assessment factors for decision-making on treatment modalities in papillary thyroid microcarcinoma with intermediate- and high-risk_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIAO Siqi , WU Xianji , SHEN Keyu ,  ZHANG Guang

Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University; Jilin Provincial Key Laboratory of Surgical Translational Medicine; Jilin Provincial Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun 130033, P. R. China;

Corresponding author：

ZHANG Guang, Email: zhangguang@jlu.edu.cn

Keywords：

papillary thyroid microcarcinoma; preoperative assessment; risk stratification

DOI：

10.7507/1007-9424.202212004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the role of preoperative evaluation indicators for decision-making on treatment modalities in papillary thyroid microcarcinoma (PTMC) with intermediate- and high-risk. Method The recent pertinent literatures on studies of risk factors influencing PTMC were collected and reviewed. Results The surgical treatment was advocated for the PTMC with intermediate- and high-risk. However, the intraoperative surgical resection range and the postoperative prognosis of patients were debated. The malignancy of cell puncture pathology was a key factor in determining the surgical protocol. The patients with less than 45 years old at surgery, male, higher body mass index, higher serum thyrotropin level, and multifocal and isthmic tumors, and nodule internal hypoecho, calcification, unclear boundary, and irregular morphology by ultrasound, as well as mutations in BRAF^V600E and telomerase reverse transcriptase gene were the risk factors for preoperative evaluation of PTMC with intermediate- and high-risk. Conclusions According to a comprehensive understanding of preoperative risk factors for PTMC with intermediate- and high-risk, it is convenient to conduct an accurate preoperative evaluation and fully grasp the patients’ conditions. Clinicians should formulate individualized surgical treatment plans for patients based on preoperative assessment and their own clinical experiences.

Citation： XIAO Siqi, WU Xianji, SHEN Keyu, ZHANG Guang. Role of preoperative assessment factors for decision-making on treatment modalities in papillary thyroid microcarcinoma with intermediate- and high-risk. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(5): 620-625. doi: 10.7507/1007-9424.202212004 Copy

1.	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
2.	Wu Q, Zhang YM, Sun S, et al. Clinical and sonographic assessment of cervical lymph node metastasis in papillary thyroid carcinoma. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(6): 823-827.
3.	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
4.	Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol, 2022, 33(1): 27-63.
5.	中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版). 中国肿瘤临床, 2016, 43(10): 405-411.
6.	杞灵斌, 詹想想, 尹哲, 等. 甲状腺微小乳头状癌的手术诊疗分析. 中国普外基础与临床杂志, 2016, 23(10): 1182-1184.
7.	Zheng W, Wang X, Rui Z, et al. Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors. Nucl Med Commun, 2019, 40(5): 477-483.
8.	Nixon IJ, Kuk D, Wreesmann V, et al. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann Surg Oncol, 2016, 23(2): 410-415.
9.	Huang H, Xu S, Wang X, et al. Patient age is significantly related to distant metastasis of papillary thyroid microcarcinoma. Front Endocrinol (Lausanne), 2021, 12: 748238. doi: 10.3389/fendo.2021.748238.
10.	Tang J, Liu HB, Yu L, et al. Clinical-pathological characteristics and prognostic factors for papillary thyroid microcarcinoma in the elderly. J Cancer, 2018, 9(2): 256-262.
11.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
12.	王岩岩, 李莉, 彭德峰, 等. 甲状腺微小乳头状癌中央区淋巴结转移的相关因素分析. 中华全科医学, 2018, 16(8): 1268-1270, 1282.
13.	孔令欣, 王照华, 殷文斌, 等. 甲状腺微小乳头状癌侧颈淋巴结转移相关危险因素与预测指标分析. 中国普通外科杂志, 2021, 30(5): 537-542.
14.	Dong Y, Wang D, Luo Y, et al. Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma. Oncol Lett, 2021, 21(3): 188. doi: 10.3892/ol.2021.12449.
15.	Choi JS, Kim EK, Moon HJ, et al. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. Endocrine, 2015, 48(1): 264-271.
16.	马琳, 孙庆贺, 张磊, 等. 体重指数对甲状腺微小乳头状癌患病风险及严重程度的影响. 国际外科学杂志, 2018, 45(12): 800-805.
17.	Aschebrook KB, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP diet and health study. Thyroid, 21(9): 957-963.
18.	Kust D, Staničić J, Mateša N. Bethesda thyroid categories and family history of thyroid disease. Clin Endocrinol (Oxf), 2018, 88(3): 468-472.
19.	高培蓉, 张震. 超声联合CT诊断家族性甲状腺微小乳头状癌的价值. 中国医科大学学报, 2019, 48(5): 472-475.
20.	Cao J, Chen C, Chen C, et al. Clinicopathological features and prognosis of familial papillary thyroid carcinoma—a large-scale, matched, case-control study. Clin Endocrinol (Oxf), 2016, 84(4): 598-606.
21.	马奎, 夏颖. 职业性放射性甲状腺癌病例诊断评价. 辐射防护通讯, 2021, 41(4): 44-46.
22.	Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab, 2017, 61(2): 180-187.
23.	Duque CS, Vélez A, Cuartas J, et al. Molecular profiling of papillary thyroid carcinomas in healthcare workers exposed to low dose radiation at the workplace. Endocrine, 2022, 76(1): 95-100.
24.	李伟, 安树才, 王磊, 等. 多灶性PTMC与单灶性PTMC转移的危险因素对比. 医学理论与实践, 2022, 35(6): 981-983.
25.	吕翠婷, 袁喆晨, 胡时雨, 等. 甲状腺乳头状微小癌中央区淋巴结转移临床病理预测因素分析. 社区医学杂志, 2022, 20(5): 258-262.
26.	Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2 309 consecutive patients. Ann Surg Oncol, 2015, 22(1): 125-131.
27.	Sapuppo G, Grasso S, Di Benedetto G, et al. Is multifocality a risk factor in low-risk papillary thyroid cancer? Endokrynol Pol, 2022, 73(6): 928-934.
28.	吴元清, 林杰, 罗佳宝, 等. 甲状腺微小乳头状癌淋巴结转移和腺外侵犯的危险因素分析. 中华普外科手术学杂志(电子版), 2021, 15(3): 319-322.
29.	孙威, 贺亮, 张浩. 美国癌症联合委员会甲状腺癌分期系统(第8版)更新解读. 中国实用外科杂志, 2017, 37(3): 255-258.
30.	Kwak JY, Kim EK, Youk JH, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid, 18(6): 609-614.
31.	王娴, 谌业荣, 张国梁, 等. 超声诊断甲状腺微小乳头状癌腺外侵犯的影响因素分析. 临床超声医学杂志, 2020, 22(6): 407-410.
32.	其阿米西·别孜尔见, 哈力木拉提·木尔提扎, 哈尔满·阿吉汉, 等. 术前血清TSH水平与甲状腺微小乳头状癌发生的相关性研究. 中国普外基础与临床杂志, 2017, 24(1): 64-69.
33.	张翊, 李强, 吴致委, 等. TSH水平与甲状腺乳头状微小癌之间的关系探讨. 中华普外科手术学杂志(电子版), 2016, 10(5): 396-398.
34.	Tam AA, Ozdemir D, Aydın C, et al. Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer. Endocrine, 2018, 59(3): 565-572.
35.	刘小女, 雷敏, 胡青青, 等. 甲状腺微小乳头状癌超声特征联合TSH检测对颈侧淋巴结转移的预测作用分析. 中国煤炭工业医学杂志, 2022, 25(6): 668-672.
36.	Kang JG, Kim YA, Choi JE, et al. Usefulness of 1-year of thyroid stimulating hormone suppression on additional levothyroxine in patients who underwent hemithyroidectomy with papillary thyroid microcarcinoma. Gland Surg, 2019, 8(6): 636-643.
37.	Kanokwongnuwat W, Larbcharoensub N, Sriphrapradang C, et al. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center. Endocrine, 2022, 77(1): 134-142.
38.	Huang LH, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett, 2018, 15(4): 4269-4277.
39.	邓强. 甲状腺微小乳头状癌患者血清甲状腺过氧化物酶抗体、甲状腺球蛋白抗体及促甲状腺激素水平变化及其临床意义. 实用医院临床杂志, 2019, 16(4): 105-108.
40.	中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版). 中华普通外科学文献(电子版), 2019, 13(1): 1-15.
41.	秦嘉黎, 张莎莎, 李刚, 等. 高频超声和超声引导下细针穿刺在诊断甲状腺微小乳头状癌中的价值比较. 临床耳鼻咽喉头颈外科杂志, 2021, 35(8): 718-723.
42.	张晓晓, 詹维伟, 周伟, 等. 术前超声检查评估甲状腺微小乳头状癌颈部淋巴结转移的临床价值. 中华医学超声杂志(电子版), 2014, 11(11): 52-56.
43.	俸均繁, 文革, 谢淑慧. 甲状腺微小乳头状癌的超声图像特征与颈部淋巴结转移的相关性. 临床超声医学杂志, 2019, 21(6): 467-469.
44.	Gong Y, Yao X, Yu L, et al. Ultrasound grayscale ratio: a reliable parameter for differentiating between papillary thyroid microcarcinoma and micronodular goiter. BMC Endocr Disord, 2022, 22(1): 75. doi: 10.1186/s12902-022-00994-9.
45.	Li JW, Chang C, Chen JY, et al. Nodule size effect on diagnostic performance of ultrasonography and computed tomography for papillary thyroid carcinoma. Curr Med Imaging Rev, 2019, 15(5): 489-495.
46.	Li L, Wang Y, Luo DH, et al. Diagnostic value of single-source dual-energy spectral computed tomography for papillary thyroid microcarcinomas. J Xray Sci Technol, 2017, 25(5): 793-802.
47.	Han ZJ, Shu YY, Lai XF, et al. Value of computed tomography in determining the nature of papillary thyroid microcarcinomas: evaluation of the computed tomographic characteristics. Clin Imaging, 2013, 37(4): 664-668.
48.	Byun BH, Jeong UG, Hong SP, et al. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by ¹⁸F-fluorodeoxyglucose PET/CT and ultrasonography. Ann Nucl Med, 2012, 26(6): 471-477.
49.	Hwang SO, Lee SW, Kang JK, et al. Clinical value of visually identifiable ¹⁸F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma. Otolaryngol Head Neck Surg, 2014, 151(3): 415-420.
50.	陈吉东, 岳林先, 张惠, 等. 微波消融与手术切除甲状腺微小乳头状癌的短期疗效及对患者生活质量的影响. 中国超声医学杂志, 2021, 37(7): 741-745.
51.	Unal B, Sezer C. Diagnostic value of ultrasound-guided fine needle aspiration biopsy in malignant thyroid nodules: utility for micronodules. Asian Pac J Cancer Prev, 2014, 15(20): 8613-8616.
52.	Zhong LC, Lu F, Ma F, et al. Ultrasound-guided fine-needle aspiration of thyroid nodules: does the size limit its efficiency? Int J Clin Exp Pathol, 2015, 8(3): 3155-3159.
53.	张中原, 崔岱, 徐刚. US-FNA及US-CNB在甲状腺微小结节中的诊断价值及影响因素分析. 川北医学院学报, 2021, 36(12): 1577-1580.
54.	Anastasilakis AD, Polyzos SA, Makras P, et al. Papillary thyroid microcarcinoma presenting as lymph node metastasis—a diagnostic challenge: case report and systematic review of literature. Hormones (Athens), 2012, 11(4): 419-427.
55.	陈浩, 周永泽, 向远航, 等. 细针穿刺细胞学检查与细针穿刺洗脱液甲状腺球蛋白检测在甲状腺乳头状癌患者颈部淋巴结转移诊断中的价值. 中华实用诊断与治疗杂志, 2022, 36(2): 190-192.
56.	Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predic-tive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010, 17(12): 3294-3300.
57.	Shi C, Guo Y, Lv Y, et al. Clinicopathological features and prognosis of papillary thyroid microcarcinoma for surgery and relationships with the BRAF^V600E mutational status and expression of angiogenic factors. PLoS One, 2016, 11(12): e0167414. doi: 10.1371/journal.pone.0167414.
58.	胡加银, 陈潇, 何霖, 等. 超声引导下细针抽吸细胞学检查联合BRAF^V600E基因检测诊断甲状腺微小乳头状癌的价值. 临床超声医学杂志, 2022, 24(2): 151-154.
59.	谢伯剑, 郑海红, 甘梅富. BRAF^V600E基因突变与甲状腺微小乳头状癌中央区淋巴结转移相关性研究. 浙江医学, 2019, 41(12): 1260-1263.
60.	Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer, 2013, 20(4): 603-610.
61.	薛金才, 刘勤江, 田尤新, 等. BRAF^V600E及TERT启动子突变在甲状腺微小乳头状癌风险评估中的价值. 中国癌症杂志, 2018, 28(5): 335-341.
62.	Kim SY, Kim HR, Kim CH, et al. Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer. Ann Thorac Med, 2017, 12(1): 36-41.
63.	广东省医学教育协会甲状腺专业委员会, 广东省基层医药学会细胞病理与分子诊断专业委员会. 甲状腺癌RET基因检测与临床应用专家共识(2021版). 中华普通外科学文献(电子版), 2022, 16(1): 1-8.
64.	Gao R, Jia X, Liang Y, et al. Papillary thyroid microcarcinoma: the inci-dence of high-risk features and its prognostic implications. Front Endocrinol (Lausanne), 2019, 10: 74. doi: 10.3389/fendo.2019.00074.

1. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
2. Wu Q, Zhang YM, Sun S, et al. Clinical and sonographic assessment of cervical lymph node metastasis in papillary thyroid carcinoma. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(6): 823-827.
3. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
4. Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol, 2022, 33(1): 27-63.
5. 中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版). 中国肿瘤临床, 2016, 43(10): 405-411.
6. 杞灵斌, 詹想想, 尹哲, 等. 甲状腺微小乳头状癌的手术诊疗分析. 中国普外基础与临床杂志, 2016, 23(10): 1182-1184.
7. Zheng W, Wang X, Rui Z, et al. Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors. Nucl Med Commun, 2019, 40(5): 477-483.
8. Nixon IJ, Kuk D, Wreesmann V, et al. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann Surg Oncol, 2016, 23(2): 410-415.
9. Huang H, Xu S, Wang X, et al. Patient age is significantly related to distant metastasis of papillary thyroid microcarcinoma. Front Endocrinol (Lausanne), 2021, 12: 748238. doi: 10.3389/fendo.2021.748238.
10. Tang J, Liu HB, Yu L, et al. Clinical-pathological characteristics and prognostic factors for papillary thyroid microcarcinoma in the elderly. J Cancer, 2018, 9(2): 256-262.
11. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
12. 王岩岩, 李莉, 彭德峰, 等. 甲状腺微小乳头状癌中央区淋巴结转移的相关因素分析. 中华全科医学, 2018, 16(8): 1268-1270, 1282.
13. 孔令欣, 王照华, 殷文斌, 等. 甲状腺微小乳头状癌侧颈淋巴结转移相关危险因素与预测指标分析. 中国普通外科杂志, 2021, 30(5): 537-542.
14. Dong Y, Wang D, Luo Y, et al. Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma. Oncol Lett, 2021, 21(3): 188. doi: 10.3892/ol.2021.12449.
15. Choi JS, Kim EK, Moon HJ, et al. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. Endocrine, 2015, 48(1): 264-271.
16. 马琳, 孙庆贺, 张磊, 等. 体重指数对甲状腺微小乳头状癌患病风险及严重程度的影响. 国际外科学杂志, 2018, 45(12): 800-805.
17. Aschebrook KB, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP diet and health study. Thyroid, 21(9): 957-963.
18. Kust D, Staničić J, Mateša N. Bethesda thyroid categories and family history of thyroid disease. Clin Endocrinol (Oxf), 2018, 88(3): 468-472.
19. 高培蓉, 张震. 超声联合CT诊断家族性甲状腺微小乳头状癌的价值. 中国医科大学学报, 2019, 48(5): 472-475.
20. Cao J, Chen C, Chen C, et al. Clinicopathological features and prognosis of familial papillary thyroid carcinoma—a large-scale, matched, case-control study. Clin Endocrinol (Oxf), 2016, 84(4): 598-606.
21. 马奎, 夏颖. 职业性放射性甲状腺癌病例诊断评价. 辐射防护通讯, 2021, 41(4): 44-46.
22. Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab, 2017, 61(2): 180-187.
23. Duque CS, Vélez A, Cuartas J, et al. Molecular profiling of papillary thyroid carcinomas in healthcare workers exposed to low dose radiation at the workplace. Endocrine, 2022, 76(1): 95-100.
24. 李伟, 安树才, 王磊, 等. 多灶性PTMC与单灶性PTMC转移的危险因素对比. 医学理论与实践, 2022, 35(6): 981-983.
25. 吕翠婷, 袁喆晨, 胡时雨, 等. 甲状腺乳头状微小癌中央区淋巴结转移临床病理预测因素分析. 社区医学杂志, 2022, 20(5): 258-262.
26. Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2 309 consecutive patients. Ann Surg Oncol, 2015, 22(1): 125-131.
27. Sapuppo G, Grasso S, Di Benedetto G, et al. Is multifocality a risk factor in low-risk papillary thyroid cancer? Endokrynol Pol, 2022, 73(6): 928-934.
28. 吴元清, 林杰, 罗佳宝, 等. 甲状腺微小乳头状癌淋巴结转移和腺外侵犯的危险因素分析. 中华普外科手术学杂志(电子版), 2021, 15(3): 319-322.
29. 孙威, 贺亮, 张浩. 美国癌症联合委员会甲状腺癌分期系统(第8版)更新解读. 中国实用外科杂志, 2017, 37(3): 255-258.
30. Kwak JY, Kim EK, Youk JH, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid, 18(6): 609-614.
31. 王娴, 谌业荣, 张国梁, 等. 超声诊断甲状腺微小乳头状癌腺外侵犯的影响因素分析. 临床超声医学杂志, 2020, 22(6): 407-410.
32. 其阿米西·别孜尔见, 哈力木拉提·木尔提扎, 哈尔满·阿吉汉, 等. 术前血清TSH水平与甲状腺微小乳头状癌发生的相关性研究. 中国普外基础与临床杂志, 2017, 24(1): 64-69.
33. 张翊, 李强, 吴致委, 等. TSH水平与甲状腺乳头状微小癌之间的关系探讨. 中华普外科手术学杂志(电子版), 2016, 10(5): 396-398.
34. Tam AA, Ozdemir D, Aydın C, et al. Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer. Endocrine, 2018, 59(3): 565-572.
35. 刘小女, 雷敏, 胡青青, 等. 甲状腺微小乳头状癌超声特征联合TSH检测对颈侧淋巴结转移的预测作用分析. 中国煤炭工业医学杂志, 2022, 25(6): 668-672.
36. Kang JG, Kim YA, Choi JE, et al. Usefulness of 1-year of thyroid stimulating hormone suppression on additional levothyroxine in patients who underwent hemithyroidectomy with papillary thyroid microcarcinoma. Gland Surg, 2019, 8(6): 636-643.
37. Kanokwongnuwat W, Larbcharoensub N, Sriphrapradang C, et al. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center. Endocrine, 2022, 77(1): 134-142.
38. Huang LH, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett, 2018, 15(4): 4269-4277.
39. 邓强. 甲状腺微小乳头状癌患者血清甲状腺过氧化物酶抗体、甲状腺球蛋白抗体及促甲状腺激素水平变化及其临床意义. 实用医院临床杂志, 2019, 16(4): 105-108.
40. 中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版). 中华普通外科学文献(电子版), 2019, 13(1): 1-15.
41. 秦嘉黎, 张莎莎, 李刚, 等. 高频超声和超声引导下细针穿刺在诊断甲状腺微小乳头状癌中的价值比较. 临床耳鼻咽喉头颈外科杂志, 2021, 35(8): 718-723.
42. 张晓晓, 詹维伟, 周伟, 等. 术前超声检查评估甲状腺微小乳头状癌颈部淋巴结转移的临床价值. 中华医学超声杂志(电子版), 2014, 11(11): 52-56.
43. 俸均繁, 文革, 谢淑慧. 甲状腺微小乳头状癌的超声图像特征与颈部淋巴结转移的相关性. 临床超声医学杂志, 2019, 21(6): 467-469.
44. Gong Y, Yao X, Yu L, et al. Ultrasound grayscale ratio: a reliable parameter for differentiating between papillary thyroid microcarcinoma and micronodular goiter. BMC Endocr Disord, 2022, 22(1): 75. doi: 10.1186/s12902-022-00994-9.
45. Li JW, Chang C, Chen JY, et al. Nodule size effect on diagnostic performance of ultrasonography and computed tomography for papillary thyroid carcinoma. Curr Med Imaging Rev, 2019, 15(5): 489-495.
46. Li L, Wang Y, Luo DH, et al. Diagnostic value of single-source dual-energy spectral computed tomography for papillary thyroid microcarcinomas. J Xray Sci Technol, 2017, 25(5): 793-802.
47. Han ZJ, Shu YY, Lai XF, et al. Value of computed tomography in determining the nature of papillary thyroid microcarcinomas: evaluation of the computed tomographic characteristics. Clin Imaging, 2013, 37(4): 664-668.
48. Byun BH, Jeong UG, Hong SP, et al. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by ¹⁸F-fluorodeoxyglucose PET/CT and ultrasonography. Ann Nucl Med, 2012, 26(6): 471-477.
49. Hwang SO, Lee SW, Kang JK, et al. Clinical value of visually identifiable ¹⁸F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma. Otolaryngol Head Neck Surg, 2014, 151(3): 415-420.
50. 陈吉东, 岳林先, 张惠, 等. 微波消融与手术切除甲状腺微小乳头状癌的短期疗效及对患者生活质量的影响. 中国超声医学杂志, 2021, 37(7): 741-745.
51. Unal B, Sezer C. Diagnostic value of ultrasound-guided fine needle aspiration biopsy in malignant thyroid nodules: utility for micronodules. Asian Pac J Cancer Prev, 2014, 15(20): 8613-8616.
52. Zhong LC, Lu F, Ma F, et al. Ultrasound-guided fine-needle aspiration of thyroid nodules: does the size limit its efficiency? Int J Clin Exp Pathol, 2015, 8(3): 3155-3159.
53. 张中原, 崔岱, 徐刚. US-FNA及US-CNB在甲状腺微小结节中的诊断价值及影响因素分析. 川北医学院学报, 2021, 36(12): 1577-1580.
54. Anastasilakis AD, Polyzos SA, Makras P, et al. Papillary thyroid microcarcinoma presenting as lymph node metastasis—a diagnostic challenge: case report and systematic review of literature. Hormones (Athens), 2012, 11(4): 419-427.
55. 陈浩, 周永泽, 向远航, 等. 细针穿刺细胞学检查与细针穿刺洗脱液甲状腺球蛋白检测在甲状腺乳头状癌患者颈部淋巴结转移诊断中的价值. 中华实用诊断与治疗杂志, 2022, 36(2): 190-192.
56. Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predic-tive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010, 17(12): 3294-3300.
57. Shi C, Guo Y, Lv Y, et al. Clinicopathological features and prognosis of papillary thyroid microcarcinoma for surgery and relationships with the BRAF^V600E mutational status and expression of angiogenic factors. PLoS One, 2016, 11(12): e0167414. doi: 10.1371/journal.pone.0167414.
58. 胡加银, 陈潇, 何霖, 等. 超声引导下细针抽吸细胞学检查联合BRAF^V600E基因检测诊断甲状腺微小乳头状癌的价值. 临床超声医学杂志, 2022, 24(2): 151-154.
59. 谢伯剑, 郑海红, 甘梅富. BRAF^V600E基因突变与甲状腺微小乳头状癌中央区淋巴结转移相关性研究. 浙江医学, 2019, 41(12): 1260-1263.
60. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer, 2013, 20(4): 603-610.
61. 薛金才, 刘勤江, 田尤新, 等. BRAF^V600E及TERT启动子突变在甲状腺微小乳头状癌风险评估中的价值. 中国癌症杂志, 2018, 28(5): 335-341.
62. Kim SY, Kim HR, Kim CH, et al. Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer. Ann Thorac Med, 2017, 12(1): 36-41.
63. 广东省医学教育协会甲状腺专业委员会, 广东省基层医药学会细胞病理与分子诊断专业委员会. 甲状腺癌RET基因检测与临床应用专家共识(2021版). 中华普通外科学文献(电子版), 2022, 16(1): 1-8.
64. Gao R, Jia X, Liang Y, et al. Papillary thyroid microcarcinoma: the inci-dence of high-risk features and its prognostic implications. Front Endocrinol (Lausanne), 2019, 10: 74. doi: 10.3389/fendo.2019.00074.

Previous Article
Application progress of mixed reality technology in hepatobiliary and pancreatic fields
Next Article
Status and progress of PD-1/PD-L1 blockades for treatment of advanced gastric cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Role of preoperative assessment factors for decision-making on treatment modalities in papillary thyroid microcarcinoma with intermediate- and high-risk

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content